Potentialities of MicroRNA Diagnosis in Patients with Bladder Cancer

Shegay, Peter; Zhavoronkov, Alex; Гайфуллин, Нуршат; Воробьев, Н. В.; Alekseev, B. Ya.; Попов, С. В.; Garazha, Andrew; Buzdin, Anton; Каприн, А. Д.

doi:10.1007/s10517-017-3935-3

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, based on performance and cost considerations, none of the commercially available urine biomarkers to date are recommended as reliable diagnostic targets both by the European Association of Urology (link to NMIBC guideline https://uroweb.org/guideline/non-muscle-invasive-bladdercancer/#5; link to MIBC guideline https://uroweb.org/guideline/bladder-cancer-muscle-invasive-andmetastatic/#6) and American Urological Association (link to NMIBC guideline https://www.auanet.org/ guidelines/bladder-cancer-non-muscle-invasive-guideline#x2517) for routine BC clinical management or for screening in high-risk populations [39][40][41][42]. The absence of urine biomarkers that can be clinically exploited and the fact that the re-activation of telomerase is a crucial mechanism of urothelial carcinogenesis (observed in 99% of urothelial carcinomas) rekindled the interest in further research on other markers indirectly influencing telomerase activation, for example, through recurrent genetic changes that have been identified in the regulatory elements of the TERT gene.…”

Section: Telomerase Reactivation In Bladder Cancer and Early-generation Of Telomerase Urinary-based Biomarkersmentioning

confidence: 99%

Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer

Zvereva

Pisarev

Hosen

et al. 2020

IJMS

View full text Add to dashboard Cite

This review summarizes state-of-the-art knowledge in early-generation and novel urine biomarkers targeting the telomerase pathway for the detection and follow-up of bladder cancer (BC). The limitations of the assays detecting telomerase reactivation are discussed and the potential of transcription-activating mutations in the promoter of the TERT gene detected in the urine as promising simple non-invasive BC biomarkers is highlighted. Studies have shown good sensitivity and specificity of the urinary TERT promoter mutations in case-control studies and, more recently, in a pilot prospective cohort study, where the marker was detected up to 10 years prior to clinical diagnosis. However, large prospective cohort studies and intervention studies are required to fully validate their robustness and assess their clinical utility. Furthermore, it may be interesting to evaluate whether the clinical performance of urinary TERT promoter mutations could increase when combined with other simple urinary biomarkers. Finally, different approaches for assessment of TERT promoter mutations in urine samples are presented together with technical challenges, thus highlighting the need of careful technological validation and standardization of laboratory methods prior to translation into clinical practice.

show abstract

Section: Telomerase Reactivation In Bladder Cancer and Early-generation Of Telomerase Urinary-based Biomarkersmentioning

confidence: 99%

Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer

Zvereva

Pisarev

Hosen

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…21,22 Studies have found some microRNAs closely related to bladder cancer. 23,24 However, the role of miR-644a in the regulation of bladder cancer remain unknown and it is not clear what specific mechanisms that these microRNAs promote or inhibit the occurrence of bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

<p>Long Non-Coding RNA BCAR4 Binds to miR-644a and Targets TLX1 to Promote the Progression of Bladder Cancer</p>

Wang

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Bladder cancer is a serious threat to human health. It is meaningful to study the pathogenesis of bladder cancer. Long non-coding RNAs (lncRNAs) are reported to promote or inhibit bladder cancer development. However, the role of lncRNA BCAR4 in the regulation of bladder cancer remains unclear. Purpose: This study was to explore the role of lncRNA BCAR4 in the progression of bladder cancer cell. Methods: RT-PCR was used to examine the expression of BCAR4 and miR-644a. CCK8 assay, colony formation assay, Transwell assay were used to detect the progression of bladder cancer cells after transfecting of indicated plasmids. Results: The expression of BCAR4 was higher in bladder cancer cell lines than normal urothelial cell line. Moreover, the expression of BCAR4 was associated with the advanced stage and metastasis of bladder cancer. Through knockdown of BCAR4, we discovered that knockdown of BCAR4 significantly decreased the proliferation, migration and invasive abilities of bladder cancer cells. Mechanically, we showed that BCAR4 can bind to miR-644a directly and targets TLX1. Moreover, we also showed that miR-644a was also highly expressed in bladder cancer cells and inhibition of miR-644a or overexpression of TLX1 can increased the migration abilities of bladder cancer caused by knockdown of BCAR4. Conclusion: We showed that BCAR4 sponged miR-644a to modulate the expression of TLX1 and promote bladder cancer development.

show abstract

Potentialities of MicroRNA Diagnosis in Patients with Bladder Cancer

Cited by 2 publications

References 12 publications

Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer

Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer

<p>Long Non-Coding RNA BCAR4 Binds to miR-644a and Targets TLX1 to Promote the Progression of Bladder Cancer</p>

Contact Info

Product

Resources

About